TCR Retrogenic Mice As a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C
Overview
Affiliations
Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, and autoimmunity. However, examination of self-tolerance mechanisms has relied primarily on transgenic mice expressing TCRs targeting well-characterized, but nonphysiologic, model Ags, such as OVA and hemagglutinin. Identifying TCRs directed against bona fide self-antigens is made difficult by the extraordinary diversity of TCRs and the low prevalence of Ag-specific clones (<10-100 naive cells per organism), limiting dissection of tolerance mechanisms restricting immunity to self-proteins. In this study, we isolated and characterized TCRs recognizing the intestinal epithelial cell receptor and colorectal cancer Ag GUCY2C to establish a model to study self-antigen-specific tolerance mechanisms. GUCY2C-specific CD4 effector T cells were isolated from immunized, nontolerant mice. Next-generation sequencing identified GUCY2C-specific TCRs, which were engineered into CD4 T cells in vitro to confirm TCR recognition of GUCY2C. Further, the generation of "retrogenic" mice by reconstitution with TCR-transduced hematopoietic stem cells resulted in normal CD4 T cell development, responsiveness to immunization, and GUCY2C-induced tolerance in recipient mice, recapitulating observations in conventional models. This retrogenic model can be employed to define self-tolerance mechanisms restricting T and B cell responses to GUCY2C to optimize colorectal cancer immunotherapy without autoimmunity.
Piroozkhah M, Aghajani A, Jalali P, Shahmoradi A, Piroozkhah M, Tadlili Y Front Oncol. 2023; 13:1277265.
PMID: 37927469 PMC: 10623427. DOI: 10.3389/fonc.2023.1277265.
Flickinger Jr J, Singh J, Yarman Y, Carlson R, Barton J, Waldman S Front Immunol. 2022; 13:855759.
PMID: 35355987 PMC: 8959893. DOI: 10.3389/fimmu.2022.855759.
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.
Lisby A, Flickinger Jr J, Bashir B, Weindorfer M, Shelukar S, Crutcher M Expert Rev Precis Med Drug Dev. 2021; 6(2):117-129.
PMID: 34027103 PMC: 8133521. DOI: 10.1080/23808993.2021.1876518.
Flickinger Jr J, Singh J, Carlson R, Leong E, Baybutt T, Barton J J Immunother Cancer. 2020; 8(2).
PMID: 32819976 PMC: 7443303. DOI: 10.1136/jitc-2020-001046.
Generation of T Cell Receptor Retrogenic Mice.
Kong Y, Jing Y, Bettini M Curr Protoc Immunol. 2019; 125(1):e76.
PMID: 31090255 PMC: 6570547. DOI: 10.1002/cpim.76.